Phase II clinical development of an HMGB1 peptide drug for ischemic stroke
A development program for an acute ischemic stroke drug using an HMGB1 peptide, conducting a global late Phase II trial and advancing decisions on whether to continue or discontinue each dose group based on an interim analysis.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.